A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
Status:
Recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
This multicenter, prospective, observational, single-arm, 26-week study will evaluate the
effectiveness, safety and tolerability of brodalumab subcutaneous injection in participants
with psoriasis with inadequate response to their current biologic agent regimen.